Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(7 sites)
Australia
Investigational Site Number : 0360002, Bruce, Australian Capital Territory Investigational Site Number : 0360006, Maroubra, New South Wales Investigational Site Number : 0360005, Sydney, New South Wales Investigational Site Number : 0360001, Albion, Queensland Investigational Site Number : 0360004, Morayfield, Queensland Investigational Site Number : 0360003, Southport, Queensland Investigational Site Number : 0360010, Melbourne, Victoria